Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SKIN vs PRCH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PRCH Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 9–1 Matrix Metrics)

PRCH Overall Winner 6-Pillar Tally: SKIN 2 – 4 PRCH Matrix Metrics: SKIN 1 – 9 PRCH

As of Nov 16, 2026, Porch Group, Inc. (PRCH) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas PRCH carries 48.6/100 (HOLD) at $20.92 (62.6x Forward P/E, 8.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SKIN vs PRCH
SKIN NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap $106.3M
TTM Revenue $289M
Forward P/E 106.4x
Beta / 30D Vol -14.22β · 192% Vol
Unified Composite Score
34.1 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (315.4% over 20 days), RSI 70
RSI-14: 69.8 · SMA20: $12.52 · SMA50: $6.25
PRCH NASDAQ Head-to-Head Winner
Porch Group, Inc. Common Stock
Services-Prepackaged Software
$20.92
-0.62% 1D
Market Cap $2.4B
TTM Revenue $530M
Forward P/E 62.6x
Beta / 30D Vol 1.59β · 114% Vol
Unified Composite Score
48.6 / 100 HOLD
Tech 26.0 Fund 44.0 Flow 55.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.6% over 20 days), RSI 58
RSI-14: 57.6 · SMA20: $19.82 · SMA50: $18.02

6-Pillar Scorecard Institutional Category Breakdown (SKIN 2 – 4 PRCH)

Columns: Metric · SKIN · PRCH
1. Valuation Multiples SKIN
Forward P/E 106.4x 62.6x
Trailing P/E 106.4x N/M
PEG Ratio 0.93x N/M
EV / Revenue 0.9x 4.9x
2. Growth & Scale PRCH
Revenue Growth (YoY) -2.1% +13.0%
Earnings Growth (YoY) +0.0% +155.3%
TTM Revenue (USD) $289M $530M
Market Cap $106.3M $2.4B
3. Profitability & Quality PRCH
Gross Margin 67.2% 72.1%
Operating Margin 2.4% 8.0%
Net Profit Margin -6.3% 1.8%
Return on Equity (ROE) -30.1% 5.6%
4. Balance Sheet & Cash Flow PRCH
Cash Generation (TTM) $17M $99M
Cash Flow Margin 5.8% 18.6%
Net Cash / Leverage $161M Net Debt (6.61x D/E) $181M Net Debt (53.60x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PRCH
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 517.4% (100th %ile) 63.6% (13th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat SKIN
OpEx & R&D Intensity 64.8% of Rev ($187M) 64.1% of Rev ($340M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Household & Personal Products Operator Insurance - Property & Casualty Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SKIN (1) vs PRCH (9)
Institutional Metric SKIN PRCH Criterion Row Edge
Market Capitalization
Scale
$106.3M $2.4B Larger Scale PRCH
Trailing P/E Ratio
Valuation
106.4x N/M Lower Multiple SKIN
Forward P/E Ratio
Valuation
106.4x 62.6x Lower Multiple PRCH
Revenue Growth (YoY)
Growth
-2.1% +13.0% Higher Growth PRCH
Operating Margin (TTM)
Profitability
2.4% 8.0% Higher Margin PRCH
Net Profit Margin
Profitability
-6.3% 1.8% Higher Margin PRCH
Return on Equity (ROE)
Capital Efficiency
-30.1% 5.6% Higher ROE PRCH
52-Week Range Position
Momentum
83% ($0–$18) 91% ($6–$22) Stronger Trend PRCH
Beta / 30D Volatility
Risk Regime
-14.22β · 192% Vol 1.59β · 114% Vol Lower Realized Risk PRCH
Unified Institutional Score
Composite Signal
34.1 / 100 (SELL) 48.6 / 100 (HOLD) Higher Composite PRCH
Trailing 12M Revenue (USD)
Operating Scale
$289M $530M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.2% 72.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.93x PEG · 0.9x EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17M ($161M Net Debt (6.61x D/E)) $99M ($181M Net Debt (53.60x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SKIN +22.98 pp
SKIN: +42.52% · PRCH: +19.54%
3M Horizon SKIN +2382.91 pp
SKIN: +2408.33% · PRCH: +25.42%
6M Horizon SKIN +2275.31 pp
SKIN: +2385.14% · PRCH: +109.83%
1Y Horizon SKIN +952.59 pp
SKIN: +1057.69% · PRCH: +105.1%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SKIN Revenue PRCH Revenue SKIN Op. Margin PRCH Op. Margin Margin Leader
FY2019 $170M $80M 8.1% -113.6% SKIN
FY2020 $120M $70M -14.4% -58.4% SKIN
FY2021 $260M $190M -15.4% -43.3% SKIN
FY2022 $370M $280M -7.1% -64.2% SKIN
FY2023 $400M $290M -32.9% -66.2% SKIN
FY2024 $330M $310M -20.3% -20.6% SKIN
FY2025 $300M $420M -6.9% 8.7% PRCH

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SKIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 517.4%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PRCH BREAKOUT
96d in phase · OBV ACCUMULATION
Current IV 63.6%
IV Percentile 13th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact PRCH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SKIN Moat Profile Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
Competes within the Household & Personal Products value chain with $106.3M market capitalization and 2.4% operating margin.
OpEx & R&D Reinvestment 64.8% of Rev ($187M)
90D Engineering Disclosures 0 Published
PRCH Moat Profile Cyclical / Execution-Driven Positioning
Insurance - Property & Casualty Operator
Competes within the Insurance - Property & Casualty value chain with $2.4B market capitalization and 8.0% operating margin.
OpEx & R&D Reinvestment 64.1% of Rev ($340M)
90D Engineering Disclosures 0 Published

Investor FAQ SKIN vs PRCH Key Questions & Quantitative Answers

As of Nov 16, 2026, Porch Group, Inc. (PRCH) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas PRCH carries 48.6/100 (HOLD) at $20.92 (62.6x Forward P/E, 8.0% operating margin). Technically, SKIN sits in a Markup phase (RSI 69.8, UNCLASSIFIED options structure) and PRCH sits in a Markup phase (RSI 57.6, BREAKOUT options structure).

PRCH leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with PRCH at +13.0% YoY revenue growth and +155.3% YoY earnings growth on $530M TTM revenue (72.1% gross margin, 8.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), SKIN cumulative revenue shifted +76.5% while PRCH shifted +425.0%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 64.1% of Rev ($340M) (0 disclosures) for PRCH.

SKIN screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas PRCH trades at 62.6x Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (18.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus PRCH (5.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, PRCH carries 63.6% implied volatility (13th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.59β · 114% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.